Beta Bionics Files Registration Statement for Proposed Initial Public Offering

Company Overview - Beta Bionics Inc is a pioneering leader in the development of advanced diabetes management solutions [1] - The company has filed a registration statement on Form S-1 with the SEC for a proposed initial public offering (IPO) of its common stock [1] - The number of shares and price range for the proposed offering have not yet been determined [1] - Beta Bionics has applied to list its common stock on the Nasdaq Global Market under the ticker symbol "BBNX" [1] IPO Details - BofA Securities Piper Sandler and Leerink Partners are acting as lead bookrunners for the proposed offering [1] - Stifel is acting as a bookrunner and Lake Street Capital Markets is acting as co-manager for the proposed offering [1] - The proposed offering will be made only by means of a prospectus [2] - Copies of the preliminary prospectus may be obtained from BofA Securities Piper Sandler or Leerink Partners [2] Regulatory Status - A registration statement on Form S-1 relating to these securities has been filed with the SEC but has not yet become effective [3] - These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective [3] Contact Information - Investor Relations Contact: Blake Beber Head of Investor Relations ir@betabionics com [4] - Media and Public Relations Contact: Karen Hynes Vice President of Marketing media@betabionics com [4]